The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Case Report: Drug-Induced Lupus

Case Report: Drug-Induced Lupus

September 14, 2021 • By Haseeb Chaudhary, MD, Prem Parajuli, MD, & Devy Setyono, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
The ECG shows widespread ST elevation, along with PR segment deviation more prominent in leads I, II, AVF and AVR, suggestive of acute pericarditis.

Figure 1. The ECG shows widespread ST elevation, along with PR segment deviation more prominent in leads I, II, AVF and AVR, suggestive of acute pericarditis.

The incidence of drug-induced lupus continues to rise as clinicians expand their therapeutic armamentarium. An estimated 15,000–30,000 cases of drug-induced lupus occur every year in the U.S. alone.1 It is a well-known, but rare, complication of commonly used medications, such as anti-hypertensive, anti-arrhythmic and anti-epileptic drugs, as well as biologic and immune checkpoint therapies.2,3

You Might Also Like
  • Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap
  • Case Report: A Lupus Patient with Abdominal Pain
  • Case Report: Metoprolol-Induced Arthralgia
Explore This Issue
September 2021

The mechanism of how drugs cause this autoimmune phenomenon is only partially understood. The complex disease pathophysiology includes such factors as the host’s acetylator status, alterations in innate and adaptive immunity, certain drugs acting as haptogens and the generation of cytotoxic metabolites, which result in an autoimmune reaction, often causing detrimental effects on the target organs.4-6  The most common presenting symptoms of drug-induced lupus overlap with idiopathic systemic lupus erythematosus (SLE). These include fever, anorexia, weight loss, fatigue and musculoskeletal symptoms.7 However, the multi-organ manifestations seen in idiopathic SLE are uncommon in drug-induced lupus.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Given the lack of diagnostic criteria, clinicians often rely on the identification of a temporal relationship between administration of the drug and the development of symptoms for diagnosis.

Case Presentation

A 35-year-old Black woman with a history of epilepsy who had taken phenytoin and topiramate for seven years presented to our hospital with a one-month history of intermittent, sharp, substernal chest pain and progressive exertional dyspnea. She denied experiencing fever, cough, flu-like symptoms, leg swelling, orthopnea, paroxysmal nocturnal dyspnea, oral ulcers, hair loss, skin rash or Raynaud’s phenomenon.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

She had visited two different urgent care facilities prior to this presentation and was prescribed over-the-counter analgesics. On arrival, her blood pressure was 120/73 mmHg, her pulse was 98 beats/minute, her temperature 36.5ºF, and she had a respiratory rate of 22 breaths/minute with normal saturation on ambient air. She had trace pedal edema with decreased breath sounds bilaterally, but an otherwise normal systemic examination.

Complete blood counts revealed a white blood cell count of 5.9×103 cells/μL (normal: 4.5–11.0×103 cells/μL), hemoglobin of 10.0 g/dL (normal: 11–13.5 g/dL) with a mean corpuscular volume of 81.9 fL (normal: 81–99 fL) and platelets of 369×103 cells/μL (normal:150–400 x103 cells/μL). Her inflammatory markers were elevated: erythrocyte sedimentation rate of 65 mm/hr (normal: 0–20 mm/hr) and a C-reactive protein of 30.93 mg/dL (normal: <0.5 mg/dL). Her troponin I was elevated at 1.8 ng/mL (normal: <0.03 ng/mL). She had normal renal and liver functions.

An evaluation for anemia revealed a ferritin level of 82 µg/mL (normal: 11–307 µg/mL), total iron binding capacity of 210 µg/dL (normal: 284–507 µg/dL), transferrin saturation of 6% (normal: 15–50%) and an iron level of 13 mcg/dL (normal: 50–212 mcg/dL). Her serum lactate dehydrogenase was 317 U/L (normal: 140–271 U/L). Her reticulocyte count, peripheral smear and haptoglobin levels were unremarkable.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Her electrocardiogram showed diffuse ST segment elevations with PR segment depressions suggestive of acute pericarditis (see Figure 1).

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: cardiac tamponade, drug-induced lupus, phenytoin, SLE Resource CenterIssue: September 2021

You Might Also Like:
  • Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap
  • Case Report: A Lupus Patient with Abdominal Pain
  • Case Report: Metoprolol-Induced Arthralgia
  • Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)